BeiGene begins dosing in Phase II trial of BGB-A317 in China to treat cHL

Biopharmaceutical company BeiGene has begun dosing patients in its Phase II clinical trial of BGB-A317 in China for the treatment of classical Hodgkin lymphoma (cHL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news